HALO
NASDAQHalozyme Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$121.81-0.39 (-0.32%)
01:30 PM07:45 PM
News · 26 weeks60+25%
2026-04-192026-10-11
Mix2990d
- Insider11(38%)
- SEC Filings7(24%)
- Other6(21%)
- Earnings2(7%)
- Leadership2(7%)
- Analyst1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Halozyme Therapeutics Inc.4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERAmendment: SEC Form 4/A filed by Halozyme Therapeutics Inc.4/A - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRHalozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European MarketsSAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to be infringing one of its MDASE patents, EP 2,797,622 (EP622) and ordered Merck's central European Market Authorization Holder and worldwide packaging and distribution hub MSD BV to refrain from manufacturing, having manufactured, offering, placing on the market and using, or importing or stocking for these purposes, Keytruda SC in Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands. The injunction also forbids MSD to facilitate infringement by its affiliates, includ
- PRHalozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® TechnologyExpanded agreement increases argenx's exclusive access to ENHANZE® from six to eight targetsSAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize ENHANZE® with two additional exclusive targets."We are pleased to expand our collaboration with argenx, a recognized leader in immunology, building on the successful development of VYVGART Hytrulo," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "The addition of two new exclusive targets further validates the value and versatility of ENHANZE
- INSIDERDirector Daly James M was granted 1,169 units of Restricted Stock Units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERSEC Form 3 filed by new insider Daly James M3 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERDirector Posard Matthew L. sold $567,661 worth of shares (5,230 units at $108.54) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 53,609 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SECHalozyme Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
- PRHalozyme Announces Appointment of Jim Daly to its Board of DirectorsSAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced the appointment of James "Jim" Daly to its Board of Directors. Mr. Daly is a highly respected biopharmaceutical executive with more than three decades of commercial leadership experience and a proven track record of shaping the profile of innovative therapies resulting in highly successful launches of respiratory, oncology and immunology therapies."We are delighted to welcome Jim back to Halozyme's Board of Directors," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "Jim brings exceptional industry knowledge, commercial expertise, strateg
- SECHalozyme Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
- SECHalozyme Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
- PRHalozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033SAN DIEGO, Sept. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 (the "Convertible Notes"). The offering size was increased from the previously announced offering size of $1.05 billion aggregate principal amount of notes. The Company also granted a 13-day option to the initial purchasers to purchase up to an additional $200 million aggregate principal amount of the Convertible Notes. The Convertible Notes are being offered and sold only to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A und
- INSIDERDirector Posard Matthew L. sold $2,046,581 worth of shares (18,996 units at $107.74) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 58,839 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SECHalozyme Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
- PRHalozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033SAN DIEGO, Sept. 16, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033 (the "Convertible Notes"). The Company also expects to grant a 13-day option to the initial purchasers to purchase up to an additional $150 million aggregate principal amount of the Convertible Notes. The Convertible Notes are to be offered and sold only to persons reasonably believed to be "qualified institutional buyers" pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").Th
- INSIDERPRESIDENT AND CEO Torley Helen exercised 60,000 shares at a strike of $18.41 and sold $6,436,711 worth of shares (60,000 units at $107.28) as part of a pre-agreed trading plan (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERDirector Appelhans Dannielle was granted 1,161 units of Restricted Stock Units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRHalozyme to Participate at Upcoming Investor ConferencesSAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Darren Snellgrove, Chief Financial Officer, are scheduled to participate and host investor meetings at the following investor conferences.Details on the Company's participation are as follows:Event: Wells Fargo 21st Annual Healthcare ConferenceFormat: Fireside Chat and 1x1 MeetingsPresentation Date: Wednesday, September 9, 2026Presentation Time: 12:45pm PT / 3:45pm ETEvent: Morgan Stanley 24th Annual Global Healthcare ConferenceFormat: Fireside Chat and 1x1 MeetingsDate: Tuesday, September 15, 2026Presentation Time:
- INSIDERSEC Form 3 filed by new insider Appelhans Dannielle3 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- INSIDERPRESIDENT AND CEO Torley Helen exercised 60,000 shares at a strike of $18.41 and sold $6,275,592 worth of shares (60,000 units at $104.59) as part of a pre-agreed trading plan (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SECHalozyme Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
- PRHalozyme Appoints Dannielle Appelhans to its Board of DirectorsSAN DIEGO, Aug. 18, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings more than 20 years of executive leadership across the biotechnology and pharmaceutical industries, with deep expertise in operations, manufacturing, and supply chain management."Dannielle brings a rare combination of operational excellence and manufacturing depth that aligns directly with our growth strategy, and we are delighted to welcome her to the Halozyme board," said Dr. Helen Torley, President and Chief Executive Officer. "As we continue to scale ENHANZE as a compounding platform engine and a
- INSIDERDirector Connaughton Bernadette sold $167,153 worth of shares (1,626 units at $102.80) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 40,418 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- ANALYSTHalozyme Therapeutics upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Halozyme Therapeutics from Market Perform to Outperform and set a new price target of $110.00
- SECSEC Form 10-Q filed by Halozyme Therapeutics Inc.10-Q - HALOZYME THERAPEUTICS, INC. (0001159036) (Filer)
HALO FAQ
6 questionsWhat does Halozyme Therapeutics Inc. do?
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for...Where does HALO stock trade?
Halozyme Therapeutics Inc. (HALO) is listed on NASDAQ.What sector and industry is HALO in?
Halozyme Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about HALO?
Halozyme Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform on 2026-08-07. Recent price targets cluster around $4700.00.What companies are similar to HALO?
Notable peers in the same industry include TPTX (Turning Point Therapeutics Inc.), CBAY (CymaBay Therapeutics Inc.), CDTX (Cidara Therapeutics Inc.). Compare HALO side-by-side with any of them on Quantisnow.How can I track HALO on Quantisnow?
Quantisnow aggregates Halozyme Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HALO to receive live email and push alerts on every new disclosure.